Search results for: 'complex therapies'

The global security market is poised to expand at a compound annual growth rate (CAGR) of 6.81% over 2018–2025. Cybersecurity is the most crucial technology segment that is projected to grow at a faster rate than the overall security market, achieving a CAGR of 9.20% over the same period. An inevitable need for advanced security solutions to contai...

The study provides an overview of insurance and repair processes when an electric vehicle (EV) is damaged in an accident. Covered regions include North America (the United States and Canada) and Europe (including the United Kingdom). The key challenges that repairers and auto insurers face when repairing an electric vehicle and the factors that ...

05 Apr 2023  |  Asia Pacific  |  Market Outlook

Asia-Pacific Pharmaceutical Industry Outlook, 2023

Disruptive Technology Adoption and Outsourcing Growth is Advancing Innovation in the Pharmaceutical Industry

Infographics

×

Asia-Pacific’s pharmaceutical market is forecast to record 4.2% growth from 2022 to 2027, with China and Japan dominating the market in terms of value. Generics dominate the regional markets based on volume, directly impacting innovator molecule uptake. Nevertheless, Asia-Pacific is establishing itself as a global innovation hub, with China, Japan,...

15 Dec 2020  |  Global  |  Frost Radar

Frost Radar™: Advanced Antibodies, 2020

A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines

Infographics

×

With advances in antibody-based therapies, bispecific antibodies (bsAbs) have gained momentum in the last few years after the regulatory approvals of Amgens blinatumomab (Blincyto®) and Chugais Hemlibra for Hemophilia A. The key advantage of bsAbs lies in their ability to bind two different epitopes or antigens, thereby overcoming the limitations o...

CDMOs are third-party vendors that offer outsourced development and manufacturing services for pharmaceutical drugs. In the small molecule manufacturing sector, CDMOs provide expert development and manufacturing services and are now an essential part of the pharmaceutical industry's value chain. The growing incidence of chronic diseases propels t...

Pharmaceutical companies spend billions of dollars in drug development because of expensive and time-consuming clinical trials, with a meager success rate. Frequent clinical visits, manual data processing, and a lack of consistent data on the effectiveness of the investigation of medical products contribute to their low success rate. Digital bio...

The procedure for accurately identifying a biomarker correlation based on a patient s genetic makeup is complex and relies on the expertise and knowledge of an oncologist, decision-support scientist, or other healthcare professional involved in the matching process. Precision oncology aims to provide oncologists with diagnosis, prognosis, and treat...

he global life science industry is in a state of flux. While the recent years have seen the advent of multiple novel technologies, such as in-vitro diagnostics (IVD), CRISPR-Cas9, virtual clinical trials, and liquid biopsy, the industry stands at a crossroad with challenges in scaling-up and commercializing such technologies. In addition, companies...

A plethora of percutaneous treatment approaches has led to clinical care innovations in cardiac interventions. The past decade witnessed more applications of novel, catheter-based treatments for structural heart diseases. Many of these non-surgical, catheter-based interventional procedures have been proven effective, consequently resulting in great...